Arbutus Biopharma Corp. (ABUS)
4.09
+0.06
(+1.49%)
USD |
NASDAQ |
Nov 13, 16:00
4.095
0.00 (0.00%)
After-Hours: 19:59
Arbutus Biopharma Price to Book Value : 9.505 for Nov. 13, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 9.505 |
| November 12, 2026 | 9.366 |
| November 11, 2026 | 9.017 |
| November 10, 2026 | 8.878 |
| November 09, 2026 | 8.645 |
| November 06, 2026 | 8.494 |
| November 05, 2026 | 8.529 |
| November 04, 2026 | 9.436 |
| November 03, 2026 | 9.017 |
| November 02, 2026 | 9.296 |
| October 30, 2026 | 9.784 |
| October 29, 2026 | 9.947 |
| October 28, 2026 | 10.04 |
| October 27, 2026 | 9.97 |
| October 26, 2026 | 9.761 |
| October 23, 2026 | 9.761 |
| October 22, 2026 | 9.784 |
| October 21, 2026 | 9.714 |
| October 20, 2026 | 10.06 |
| October 19, 2026 | 9.831 |
| October 16, 2026 | 9.807 |
| October 15, 2026 | 9.97 |
| October 14, 2026 | 9.738 |
| October 13, 2026 | 9.552 |
| October 12, 2026 | 9.645 |
| Date | Value |
|---|---|
| October 09, 2026 | 9.807 |
| October 08, 2026 | 9.714 |
| October 07, 2026 | 9.97 |
| October 06, 2026 | 10.41 |
| October 05, 2026 | 10.85 |
| October 02, 2026 | 10.34 |
| October 01, 2026 | 10.60 |
| September 30, 2026 | 11.11 |
| September 29, 2026 | 3.582 |
| September 28, 2026 | 3.712 |
| September 25, 2026 | 3.705 |
| September 24, 2026 | 3.728 |
| September 23, 2026 | 3.705 |
| September 22, 2026 | 3.827 |
| September 21, 2026 | 3.819 |
| September 18, 2026 | 3.827 |
| September 17, 2026 | 3.873 |
| September 16, 2026 | 3.858 |
| September 15, 2026 | 3.865 |
| September 14, 2026 | 3.919 |
| September 11, 2026 | 3.911 |
| September 10, 2026 | 3.911 |
| September 09, 2026 | 3.949 |
| September 08, 2026 | 3.957 |
| September 04, 2026 | 3.934 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Gossamer Bio, Inc. | -- |
| ACADIA Pharmaceuticals, Inc. | 2.335 |
| Alnylam Pharmaceuticals, Inc. | 6.131 |
| Anika Therapeutics, Inc. | 1.305 |
| Savara, Inc. | 8.843 |
Price to Book Value Related Metrics
| PE Ratio | 3.652 |
| PS Ratio | 4.422 |
| Price to Free Cash Flow | 3.663 |
| Price | 4.09 |
| Earnings Yield | 27.38% |
| Market Cap | 815.04M |
| Operating PE Ratio | 5.517 |
| Normalized PE Ratio | 3.673 |